Golidocitinib
A Janus kinase inhibitor used in cancer treatment
| Golidocitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Golidocitinib is a Janus kinase (JAK) inhibitor that is being investigated for its potential use in the treatment of various cancers. It specifically targets the JAK1 enzyme, which plays a crucial role in the signaling pathways that regulate immune function and cell growth.
Mechanism of Action[edit | edit source]
Golidocitinib functions by selectively inhibiting the activity of the JAK1 enzyme. The JAK family of enzymes, which includes JAK1, JAK2, JAK3, and TYK2, is involved in the signaling pathways of various cytokine receptors. By inhibiting JAK1, golidocitinib disrupts the JAK-STAT signaling pathway, which is often dysregulated in cancer cells, leading to uncontrolled cell proliferation and survival.
Clinical Development[edit | edit source]
Golidocitinib is currently undergoing clinical trials to evaluate its efficacy and safety in treating different types of cancers, including lymphoma and solid tumors. The drug is being studied both as a monotherapy and in combination with other anticancer agents.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of golidocitinib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to be orally bioavailable, allowing for convenient administration. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.
Potential Side Effects[edit | edit source]
As with other JAK inhibitors, golidocitinib may cause side effects related to its immunosuppressive action. Common adverse effects observed in clinical trials include neutropenia, anemia, and increased risk of infections. Monitoring of blood counts and liver function tests is recommended during treatment.
Research and Development[edit | edit source]
Research on golidocitinib is focused on understanding its full therapeutic potential and optimizing its use in combination therapies. Ongoing studies aim to identify biomarkers that predict response to treatment and to explore its effects on the tumor microenvironment.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
